Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 26 Feb 2002 |
| Genmab, annual report 2001 | 26 Feb 2002 |
| Genmab, HUMAX-CD4 awarded fast track status from FDA | 21 Feb 2002 |
| Genmab, to present at the 2002 BIO CEO & Investor conference in New York | 20 Feb 2002 |
| Genmab, amendment to Stock Exchange notice of February 15, 2002 on grant of warrants in Genmab | 20 Feb 2002 |